

HCV Directly Acting Antivirals & RBV

Charts revised April 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

Table with columns for DCV, ELB/GZR, G/P, LED/SOF, OBV/PTV/r, OBV/PTV/r+DSV, RDV, SOF, SOF/VEL, SOF/VEL/VOX, RBV. Rows include Anaesthetics and muscle relaxants, Analgesics, Anthelmintics, and Antiarrhythmics.

Table with columns for DCV, ELB/GZR, G/P, LED/SOF, OBV/PTV/r, OBV/PTV/r+DSV, RDV, SOF, SOF/VEL, SOF/VEL/VOX, RBV. Rows include Antibacterials.

For personal use only. Not for distribution.

Key to symbols

Legend for symbols: red dot for non-coadministration, orange square for clinical interaction, yellow triangle for weak interaction, green diamond for no interaction.

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways and routes of clearance.
Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX. We aim to ensure that information is accurate and consistent with current knowledge and practice.

HCV Directly Acting Antivirals & RBV

Charts revised April 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Anticoagulant, anti-platelet and fibrinolytic											
Abciximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acenocoumarol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anagrelide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Apixaban	▲	▲	▲	▲	◆	◆	◆	◆	▲	▲	◆
Caplacizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clopidogrel	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Dabigatran	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Dalteparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Danaparoid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Edoxaban	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enoxaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluidione	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fondaparinux	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenprocoumon	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prasugrel	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rivaroxaban	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Streptokinase	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticagrelor	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Ticlopidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tinzaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Warfarin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anticonvulsants											
Carbamazepine	◆	●	◆	◆	●	●	◆	◆	◆	◆	◆
Clonazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eslicarbazepine	◆	●	◆	◆	●	●	◆	◆	◆	◆	◆
Ethosuximide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamotrigine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxcarbazepine	◆	●	◆	◆	●	●	◆	◆	◆	◆	◆
Perampanel	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenobarbital	◆	●	◆	◆	●	●	◆	◆	◆	◆	◆
Phenytoin	◆	●	◆	◆	●	●	◆	◆	◆	◆	◆
Pregabalin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Primidone	◆	●	◆	◆	●	●	◆	◆	◆	◆	◆
Retigabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Anticonvulsants continued											
Rufinamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sodium valproate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tiagabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valproate semisodium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valproic acid (Divalproex)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antidepressants											
Agomelatine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amitriptyline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bupropion	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desvenlafaxine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Dosulepin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doxepin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Duloxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Escitalopram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lithium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mianserin	◆	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moclobemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nefazodone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nortriptyline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Paroxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Reboxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tianeptine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Venlafaxine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

Table with columns for drug classes and specific drugs, and rows for various HCV DAAs and RBV. Includes categories like Contraceptives and hormone replacement, and Erectile dysfunction agents.

Table with columns for drug classes and specific drugs, and rows for various HCV DAAs and RBV. Includes categories like Gastrointestinal agents, HCC Therapies, Hepatitis B Drugs, Hepatitis C Directly Acting Antivirals (DAAs), and Hepatitis D Directly Acting Antivirals (DAAs).

For personal use only. Not for distribution.

Key to symbols

Table defining symbols: red dot for no coadministration, orange square for clinical interaction, yellow triangle for potential interaction, and green diamond for no interaction.

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways and routes of clearance.
Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX. We aim to ensure that information is accurate and consistent with current knowledge and practice.

HCV Directly Acting Antivirals & RBV

Charts revised April 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Herbals/Supplements/Vitamins											
Aloe vera	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Black cohosh	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (<i>U. tomentosa</i>)	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enteric feeds	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eucalyptus globulus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginger (<i>Z. officinale</i>)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginseng	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Goldenseal (<i>H. canadensis</i>)	■	■	■	■	■	■	◆	◆	◆	◆	◆
Grape seed extract	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Grapefruit juice	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Green tea (<i>C. sinensis</i>)	▲	▲	▲	▲	▲	▲	◆	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Inula racemosa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Kava kava	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
L-lysine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Milk thistle	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Niacin (Vitamin B3)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Omega-3-6-9 fatty acids	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oral nutritional supplements	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oregano oil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Retinol (Vitamin A)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riboflavin (Vitamin B2)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Saw Palmetto (<i>S. repens</i>)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
St John's wort	●	●	●	●	●	●	●	●	●	●	◆
Thiamine (Vitamin B1)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Turmeric (curcumin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valerian	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin E	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
HIV Drugs											
<i>Entry/Integrase Inhibitors</i>											
Albuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bictegravir/FTC/TAF	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (LA)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/rilpivirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elvitegravir/cobi /FTC/TAF	■	●	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elvitegravir/cobi/FTC/TDF	■	●	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enfuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fostemsavir	◆	●	▲	▲	▲	▲	▲	▲	▲	▲	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maraviroc	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
<i>NRTIs</i>											
Dapivirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Doravirine/3TC/TDF	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Efavirenz	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Etravirine	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Nevirapine	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine/dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine/FTC/TAF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
<i>NRTIs</i>											
Abacavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Didanosine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Emtricitabine (FTC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine + TAF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine + TDF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Stavudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir-DF (TDF)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zidovudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
<i>Protease Inhibitors</i>											
Atazanavir alone	◆	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Atazanavir/cobicistat	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Atazanavir + ritonavir	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Darunavir/cobicistat	◆	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Darunavir/cobi/FTC/TAF	◆	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Darunavir + ritonavir	◆	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Fosamprenavir	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Indinavir	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Lopinavir	◆	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Ritonavir	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆
Tipranavir	■	●	●	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Hypertension/heart failure agents											
Acebutolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aliskiren	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ambrisentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amiloride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benazepril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bosentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bumetanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Candesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Captopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorothiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlortalidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clevidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doxazosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enalapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eplerenone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epoprostenol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fosinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indapamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Irbesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isradipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ivabradine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lacidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lercanidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lisinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Losartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Macitentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methyldopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Olmesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Perindopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prazosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Quinapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ramipril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranolazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilmenidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riociguat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sacubitril/valsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Selexipag	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sildenafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Spironolactone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telmisartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Torsemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trandolapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Treprostinil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Xipamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zofenopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Illicit/Recreational											
Alcohol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cannabis	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carfentanil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cocaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ecstasy (MDMA)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etizolam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fentanyl (Recreational)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mephedrone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methamphetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phencyclidine (PCP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Immunosuppressants											
Adalimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alemtuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anakinra	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azathioprine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baricitinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Basiliximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Belimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bimekizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brodalumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Canakinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciclosporin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eculizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etanercept	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fingolimod	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Golimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Guselkumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Infliximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ixekizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirikizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mycophenolate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Natalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pirfenidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ravulizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Risankizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sarilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Secukinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sirolimus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Siltuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tacrolimus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tildrakizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tocilizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tralokinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Upadacitinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ustekinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vedolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lipid Lowering Agents											
Alirocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atorvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bezafibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Evolocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fenofibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fish oils	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gemfibrozil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lovastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Omega-3-6-9 fatty acids	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pitavastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pravastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rosuvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Simvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised April 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Other Drugs											
Acamprosate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acetazolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Activated charcoal	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Allopurinol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atomoxetine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bamlanivimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betahistine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bimatoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brolucizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Burosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcitonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium carbimide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium resonium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cannabidiol (CBD)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbimazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carisoprodol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Casirivimab/imdevimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilostazol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colchicine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colestyramine	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Conivaptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Convalescent plasma (COVID-19)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
COVID-19 vaccines	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Crizanlizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclobenzaprine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyproterone acetate	▲	▲	▲	▲	▲	▲	◆	◆	◆	◆	◆
Cytisine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Darbepoetin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Deferiprone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Denosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamfetamine	▲	▲	▲	▲	▲	▲	◆	◆	◆	◆	◆
Dextromethorphan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Donepezil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dorzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eliglustat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emicizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epoetin alfa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etelcalcetide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Faricimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flibanserin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gadopentetate (gadolinium)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glycerol phenylbutyrate	▲	▲	▲	▲	▲	▲	◆	◆	◆	◆	◆
Goserelin acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Guanfacine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Idarucizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Influenza vaccine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Other Drugs continued											
Interferon beta	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isotretinoin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanadelumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanreotide	▲	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Lebrikizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Leuprorelin acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levothyroxine	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lofexidine	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lumacaftor/ivacaftor	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Magnesium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mepolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methimazole (Thiamazole)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Modafinil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naftidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nalmefene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nusinersen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orlistat	▲	▲	▲	▲	▲	▲	◆	◆	◆	◆	◆
Penicillamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propylthiouracil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Protamine sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranibizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Romozosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rozanolixizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sevelamer	▲	▲	▲	▲	▲	▲	◆	◆	◆	◆	◆
Strontium ranelate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

◆	These drugs should not be coadministered
▲	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised April 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Oxytocics											
Ergometrine (ergonovine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mifepristone	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Parkinsonism Agents											
Benzotropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pramipexole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Procyclidine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ropinirole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
PBC Agents											
Obeticholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ursodeoxycholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Steroids											
Beclometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Budesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciclesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamethasone ≤16 mg	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamethasone >16 mg	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fludrocortisone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flunisolide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylprednisolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednicarbate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Triamcinolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Urological Agents											
Alfuzosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Finasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirabegron	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆
Silodosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Solifenacin	◆	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.